RxDoctor Payments Data

Melanie Smith, MD

Ophthalmology · Conway, ARNPI 1023092343

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $518, 8.9 times the $58 reported in 2019.

$1,167in general payments, 2019–2025

Across 52 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$232
  • Bausch & Lomb Americas Inc.$204
  • Biotissue Holdings Inc.$139
  • Rxsight Inc$98
  • AbbVie$93
  • Amgen$67
  • plus $334 from 12 others

What the payments were for

  • Food & beverage$1,167100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,167 in reported general payments places this provider in the 60th percentile of 125 ophthalmology providers in Arkansas.

See all ophthalmology providers in Arkansas

Medicare billing

Part B allowed, 2024
$412,667
Medicare patients
1,519
Services billed
4,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine25$19,571
ProlensaBromfenac Sodium43$14,740
LumiganBimatoprost18$8,689
Latanoprost763$7,694
Prednisolone Acetate166$7,467
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat378$7,412
Cyclosporine14$6,314
Timolol Maleate302$5,148
Travoprost49$4,782
Brimonidine Tartrate206$3,673
Alphagan PBrimonidine Tartrate13$2,462
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,701
Dorzolamide Hcl66$1,334
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha33$351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$93$30,72156 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$22$14,74043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 125 ophthalmology providers in Arkansas.

Other ophthalmology in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →